CreaCell completes its offer with Cytogenetics services dedicated to mammalian cells. When engineering new recombinant cell lines, controles of global genome integrity (karyotype) or insertion of a transgene (F.I.S.H.) are crucial steps of Quality Control because abnormalities may seriously compromise a project. The new Cytogenetic technologies will both serve our in-house cell line developments as well as external demands.
CreaCell settles in Biopolis, a seedbed centre located in La Tronche, in vicinity of Grenoble University Hospital and School of Medicine and research laboratories. Biopolis provides us access to technological facilities, including P2 laboratory dedicated to CreaCell's activities.
NOVEMBER
2006, SHANGHAI, China
At the end of November CreaCell was in Shanghai in order to discuss terms of a technical partnership with Pr. Ji Zhang from State Key Laboratory of Medical Genomics, Ruijin Hospital.
October 25-27, 2006 - CreaCell at EuroBiO 2006.
EuroBiO 2006, the Tenth European Biotech Crossroads in Paris. Meet us to get informed about the outsoursing of mammalian cell engineering. More information on EuroBiO.
EuroBiO 2006, the Tenth European Biotech Crossroads in Paris. Meet us to get informed about the outsoursing of mammalian cell engineering. More information on EuroBiO.
October 6th, 2006 - European BioAlpine Convention.
This first edition of European BioAlpine Convention will focus on Neuroscience. More information on European BioAlpine Convention
This first edition of European BioAlpine Convention will focus on Neuroscience. More information on European BioAlpine Convention
October 5th, 2006 - CreaCell is one of the sponsors of the Annual Topic Day of the Albert Bonniot Institute.
The topic will be "iRNA and repeated sequences, between silence and transcriptional awakening".
The topic will be "iRNA and repeated sequences, between silence and transcriptional awakening".
Download the programme (french)>
In drug discovery, lead optimisation and safety pharmacology, cell line expressing specific ionic channels are powerful tools when combined with patch clamping technologies. With the emergence of dedicated instruments to automated patch-clamping (planar patch clamp technique), CreaCell has started, in partnership with CEA Biochip laboratory, the development of new ion channel cell lines. Those clonal recombinant cells are especially adapted to suspension culture, allowing a fast and efficient analysis of ionic currents with planar patch-clamp systems. Cells are also compatible with conventional patch clamp instruments. For more information, please contact us.
The company now offers a new service for leads and targets development. This service is a set of basic functional assays based on mammalian cell lines. CreaCell combines this service with cell line development and cell production to address growing demand it has identified in both pharmaceutical and biotechnology industries. “In vitro functional assays' service integrates our mammalian cell engineering platform and allows these companies to find a more complete solution to outsource the management of their cell biology projects” said Pierre-Yves Perche, CreaCell’s CEO. Press release : article from Biotech Info - L'Usine Nouvelle, march 16th, 2005 (french).
CreaCell joins the CEA Biochip laboratory to develop instruments for automated electrophysiology.
The pharmaceutical industry needs sturdiness and precise technologies in order to screen a large number of compounds against ion channel targets. The CEA Biochip laboratory, in close association with the Leti, started an ambitious program to develop planar patch-clamp technology. The current prototype allows
fast simultaneous recordings of up to nine individual cells (at the same time). In this context, CreaCell and the Biochip laboratory have initiated a collaboration to create specific ionic channel recombinant cell lines. These cells are very precious tools to validate and improve the first planar patch-clamp demonstrator. During this one year partnership, CreaCell is bringing its expertise
in mammalian cell engineering to adapt dedicated cells to this innovative equipment. In exchange, the Biochip laboratory is sharing its expertise in the field of ionic channel analysis to optimize the engineering of functional and relevant cell lines.
The pharmaceutical industry needs sturdiness and precise technologies in order to screen a large number of compounds against ion channel targets. The CEA Biochip laboratory, in close association with the Leti, started an ambitious program to develop planar patch-clamp technology. The current prototype allows
fast simultaneous recordings of up to nine individual cells (at the same time). In this context, CreaCell and the Biochip laboratory have initiated a collaboration to create specific ionic channel recombinant cell lines. These cells are very precious tools to validate and improve the first planar patch-clamp demonstrator. During this one year partnership, CreaCell is bringing its expertise
in mammalian cell engineering to adapt dedicated cells to this innovative equipment. In exchange, the Biochip laboratory is sharing its expertise in the field of ionic channel analysis to optimize the engineering of functional and relevant cell lines.
SARL
CreaCell 2008. All rights reserved | Legal
obligations